Microbes in lung cancer initiation, treatment, and outcome: Boon or bane?

Abstract

Lung cancer is the top reason for cancer-related deaths worldwide. The 5-year overall survival rate of lung cancer is approximately 20 % due to the delayed diagnosis and low response rate to regular treatments. Microbiota, both host-microbiota and alien pathogenic microbiota, have been investigated to be involved in a complicated and contradictory relationship with lung cancer initiation, treatments, and prognosis. Disorders of certain host-microbiota and pathogen infection are associated with the risk of lung cancers based on epidemiological evidence, and antibiotics (ATBs) could dramatically impair anti-cancer treatment efficacy, including chemotherapy and immunotherapy. Moreover, probiotics and microbe-mediated drugs are potential approaches to enhance regular anti-tumor treatments. Therefore, the knowledge of the complex dual effect of microbes on lung cancer is beneficial to take their essence and remove their dross. This review offers insight into the current trends and advancements in microbiota or microbial components related to lung cancer.

• Authors: Haoyue Guo, Lishu Zhao, Junjie Zhu, Peixin Chen, Hao Wang, Minlin Jiang, Xiaogang Liu, Hui Sun, Wencheng Zhao, Zixuan Zheng, Wei Li, Bin Chen, Qiyu Fang, Menghang Yang, Yayi He, Yang Yang
• Journal: Seminars in cancer biology (Semin Cancer Biol) Vol. 86 Issue Pt 2 Pg. 1190-1206 (11 2022) ISSN: 1096-3650 [Electronic] England
• PMID: 34029741 (Publication Type: Journal Article, Review, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2021. Published by Elsevier Ltd.

Topics

• Humans
• Microbiota
• Lung Neoplasms (drug therapy, etiology)
• Immunotherapy
• Probiotics (therapeutic use)
• Prognosis